China Heparin Industry Report, 2010
  • Dec/2010
  • Hard Copy
  • USD $1,600
  • Pages:63
  • Single User License
    (PDF Unprintable)       
  • USD $1,500
  • Code: JMH002
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,100
  • Hard Copy + Single User License
  • USD $1,800
      
Although it is with rich source of heparin raw materials, China lags behind in the manufacturing technologies for heparin drugs. Chinese heparin industry presents mainly the exportation of heparin API (Active Pharmaceutical Ingredients) and the importation of heparin drugs.

In 2009, China’s heparin API export volume reached 13.4 trillion units, accounting for 47.5% of the world’s total heparin API supply. The overseas markets of China heparin and its salt and the exporting enterprises are relatively concentrated in distribution. During the period from January to October of 2010, the top five export destinations of China’s heparin and its salt were France, Germany, the USA, Austria and Italy, altogether taking 88% of China’s heparin API export value in the same period. In H1 2010, the top four Chinese exporting enterprises of heparin and its salt include Shenzhen Hepalink Pharmaceutical Co., Ltd, Changzhou Qianhong Bio-Pharma Co., Ltd, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd, and Yantai Dongcheng Biochemicals Co., Ltd, with a share of 79% in all of China’s heparin API export value in the same period.     

Export Destinations of China Heparin and Its Salt, Jan.-Oct., 2010 (by Value)
 2010121503.gif
Source: ResearchInChina

Heparin drugs, the downstream products of heparin API, are essential antithrombotic drugs. With the explosive population of cardio-cerebrovascular sufferers in China, the market share of heparin drugs keeps increasing year by year. Taking low-molecular weight heparin preparation with a 87.4% share of China’s heparin drugs market (2009) for example, the market size grew at an annual rate of 18% between 2006 and 2009. And in 2009, it touched RMB 1.11 billion.

China Low-Molecular-Weight Heparin Drug Market Size, 2006-2009 (Unit: RMB100M)
 2010121504.gif
Source: Medical Economic News; ResearchInChina

Yet, Chinese market of heparin drugs, in particular the market of low-molecular weight heparin, is dominated by foreign brands on account of technology barriers although China is the world’s key supplier of heparin sodium API.

In terms of low-molecular heparin sodium market, the four foreign brands including France-based Sanofi, America-based Pfizer Pharmaceuticals and Abbott Laboratories, Italy-based ALFA WASSERMANN took a sizable lead of 83.8% market share in 2009. In particular, France-based Sanofi, whose market share accounted for 54.5%, continued to rank the first place. But among the domestic enterprises, Shandong QILU Pharmaceutical takes the lead with the market share no more than 7.4%. In low-molecular heparin calcium market, GlaxoSmithKline topped the list in 2009 with the market share of 59%, far ahead of China-based Hebei Changshan Biochemical Pharmaceutical, runner-up with the market share of 12%.

The report not only analyzes the international operating environment of China heparin industry, the status quo and competition pattern of Chinese heparin API and heparin drug market, but elaborates the operation and development prospect of relatively competitive Chinese manufacturers of heparin API and/or preparations.
1 Profile of Heparin Industry
1.1 Definition & Classification
1.2 Industry Chain

2 International Operating Environment of Heparin Industry
2.1 Demand of Heparin Medicine
2.2 Distribution of Heparin Medicine Demand
2.3 Heparin API Demand
2.4 Overseas Competitors
2.4.1 Organon
2.4.2 SPL
2.4.3 Sanofi-Aventis
2.4.4 GlaxoSmithKline
2.4.5 Pfizer Pharmaceuticals Limited
2.5 Related Policy
2.6 Market Forecast

3Current Development of China Heparin API Industry
3.1 Market Overview
3.2 Demand & Supply
3.3 Competition Pattern
3.4 Dynamics
3.5 Related Policy
3.6 Market Forecast

4 Current Development of China Heparin Preparation Industry
4.1 Overview of Antithrombotic Drugs
4.2 Market Overview
4.3 Demand & Supply
4.4 Competition Pattern
4.5 Dynamics & Patents
4.6 Market Forecast

5 China’s Import & Export of Heparin
5.1 Exporting Trade
5.1.1 Export Quantity and Prices
5.1.2 Export Destinations
5.1.3 Chinese Exporting Enterprises
5.2 Import Trade

6 Heparin Manufacturers in China
6.1 Shenzhen Hepalink Pharmaceutical
6.1.1 Profile
6.1.2 Operation
6.1.3 Dynamics
6.2 Changzhou Qianhong Bio-Pharma 
6.2.1 Profile
6.2.2 Operation
6.2.3 Dynamics
6.3 Nanjing King-Friend Biochemical Pharmaceutical
6.3.1 Profile
6.3.2 Operation
6.4 Yantai Dongcheng Biochemicals
6.4.1 Profile
6.4.2 Operation
6.5 Tianjin Chase Sun Pharmaceutical
6.5.1 Profile
6.5.2 Operation
6.5.3 Dynamics
6.6 Hebei Changshan Biochemical Pharmaceutical 
6.6.1 Profile
6.6.2 Operation
6.6.3 Dynamics
6.7 Wanbang Biopharmaceuticals
6.7.1 Profile
6.7.2 Operation
6.7.3 Dynamics
Heparin Industry Chain
Sales of Heparin Drugs Worldwide, 2003-2012E
Distribution of Heparin Drug Consumption Worldwide, 2009
Distribution of Heparin API Demand Worldwide, 2009
Heparin Sodium Operating Income and Growth of Sanofi-Aventis, 2007-2009
Forecast of Global Heparin Drug Market Development
Heparin API Export Scale of China and Its Percentage in the World Total, 2009
Number of Slaughtered Fattened Hogs (Head) and Year-end Number of Hogs (Head) of China, 2003-2009
Price Trend of Crude Sodium Heparin in China, 2007-2009
World’s Major Manufacturers of Heparin Sodium API, Jan.-Sep., 2009
Heparin Sodium API Supply in China and the World and China’s Share, 2011-2012
China Antithrombotic Drug Market Size and Growth Rate, 2003-2009
Distribution of Three Major Categories of Antithrombotic Drugs in China, Mar., 2009
Proportion of China-made Clopidogrel Sulfate and Ozagrel Products in Antithrombotic Drugs, 2005-2009
Market Shares of Key Anticoagulant Medicines of China, Sep.2008-Sep.2009
Proportion of Lumbrokinase Products of China in Anticoagulant Medicines, 2005-2009
Chinese Market Scale of Heparin Preparation Products, 2009
Proportion of Low-molecular Heparin Calcium and Low-molecular Heparin Sodium in Anticoagulant Medicines of China, 2005-2009
Market Demand for Heparin Sodium Injection Solution in China, 2007-2012
Competition Pattern of China Low-Molecular-Weight Heparin Sodium Market, 2009
YoY Growth Rate for Sales of Main Competitive Enterprises of Low-molecular Weight Heparin Sodium in China, 2009
Competition Pattern of China Low-Molecular-Weight Heparin Calcium Market, 2009
YoY Growth Rate for Sales of Main Competitive Enterprises of Low-molecular Weight Heparin Calcium in China, 2009
Main Patents for Low-Molecular-Weight Heparin
China Low-Molecular-Weight Heparin Drug Market Size, 2006-2014
Export of Key Western Medicines of China, Jan.-Jun. 2009
China’s Export Volume and Price Trend of Heparin Products, 2002-2010
Countries to which China Heparin and Its Salt Get Exported, Jan.-Oct., 2010
Main Chinese Exporting Enterprises of Heparin API and Their Percentages, Jan.-Sep., 2009
Import Volume and Unit Price Trend of Heparin Products in China, 2008-2010 
Destinations of China’s Heparin Product Imports, 2008-2010 
Import Origins of China Heparin Products, 2008-2010 
Heparin Sodium API Operating Income of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007-2009
Heparin Sodium API Revenue of Shenzhen Hepalink Pharmaceutical Co., Ltd by Product, 2007-2009
Heparin Sodium API Revenue of Shenzhen Hepalink Pharmaceutical Co., Ltd by Region, 2007-2009
Client Distribution of Heparin Sodium API Sales of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007-2009
Total Profit of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007-2009
Operating Income Structure of Main Products of Changzhou Qianhong Bio-Pharma Co., Ltd, Jan.-Jun., 2010
Sales Revenue of Heparin Sodium API and Injection Solution of Changzhou Qianhong Bio-Pharma Co., Ltd., 2007-2010
Heparin Export Value and Percentage of Changzhou Qianhong Bio-Pharma Co., Ltd., 2007-2009
Top Five Clients of Heparin Sodium API of Changzhou Qianhong Bio-Pharma Co., Ltd, 2009-2010
Operating Income and Total Profit of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd, 2007-2008
Heparin API Export of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., Jan.-Sep., 2009
Operating Income and Profit of Yantai Dongcheng Biochemicals Co., Ltd, 2007-2008
Heparin API Export of Yantai Dongcheng Biochemicals Co., Ltd, Jan.-Sep., 2009
Operating Income and Net Income of Tianjin Chase Sun Pharmaceutical Co., Ltd., 2007-2010
Operating Income (by Product) of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2009
Heparin Calcium Sales Revenue and YoY Growth of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2007-2009
Gross Margin of Molecular Heparin Calcium of Tianjin Chase Sun Pharmaceutical Co., Ltd., 2007-2009
Operating Income and Profit of Hebei Changshan Biochemical Pharmaceutical Co., Ltd, 2007-2008 
Net Income of Wanbang Biopharmaceuticals, 2007-2010

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号